Equity Overview
Price & Market Data
Price: $13.75
Daily Change: +$0.87 / 6.33%
Range: $12.88 - $13.75
Market Cap: $22,079,200
Volume: 828
Performance Metrics
1 Week: -0.83%
1 Month: 3.38%
3 Months: -8.93%
6 Months: 14.06%
1 Year: 891.7%
YTD: 18.47%
Company Details
Employees: 1
Sector: Health services
Industry: Medical/Nursing services
Country: United States
Details
Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524 for the prevention, diagnosis, theragnosis or treatment of diseases in humans, including ulcerative colitis; FIN-525 for the treatment of Crohn's disease; and other microbiome product candidates. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; and license agreements with Skysong Innovations LLC, OpenBiome, Arizona State University, and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Boston, Massachusetts.